PriceTracker GLP-1

Status

ItemStatusSinceSource
FDA drug shortage list, semaglutide injectionResolvedFeb 21, 2025FDA drug shortage database
Grace period for 503A pharmaciesEndedApr 2025FDA, 4/28/2025 update
Grace period for 503B outsourcing facilitiesEndedMay 22, 2025FDA, 4/28/2025 update
503A copies of an approved drugFDA does not intend to act at four or fewer prescriptions a monthApr 1, 2026FDA, 4/1/2026 update
503B bulks listFDA proposed excluding semaglutide; comments closed Jun 29, 2026Apr 30, 2026FDA press announcement
Mass-marketed compounded GLP-1sFDA announced intent to restrict GLP-1 APIs for themFeb 6, 2026FDA press announcement
FDA approval of compounded versionsNot FDA-approvedStandingFDA compounding Q&A

FDA’s shortage list today

Straight from FDA’s drug shortage database, last updated by FDA in October 2026.

  • semaglutide: being discontinued (Rybelsus).
  • tirzepatide: not on the list.
  • liraglutide: in shortage (Liraglutide, Saxenda, Victoza); being discontinued (Liraglutide, Saxenda).

FDA drug shortage database · read through openFDA · discontinuation is a maker’s decision, not a shortage

In the regulator’s own words

"Tirzepatide and semaglutide do not currently appear on the 503B bulks list or on FDA’s drug shortage list."
FDA, 4/1/2026 update, read October 2026
"For a state-licensed pharmacy or physician compounding, dispensing or distributing semaglutide injection products under section 503A of the FD&C Act, the period of enforcement discretion (described below) has ended."
FDA, 4/28/2025 update, read October 2026
"Compounded drugs are not FDA-approved. This means that FDA does not verify the safety, effectiveness or quality of compounded drugs before they are marketed."
FDA, Compounding and the FDA: Questions and Answers, read October 2026

This page reports what the regulator has published, in its words. It is not legal or medical advice.

Statuses change. Prices change more.

One email a week: the cheapest GLP-1 program and any real price moves.

Compare every GLP-1